Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial

Figure 2

Incidence rates of most frequently reported adverse events stratified by how many injections of ranibizumab the patient received before adverse event (AE) occurred. None of the most frequently reported adverse events occurred more frequently with higher number of injections. Percentages are based on the total number of AEs (2687 AEs = 100%). Figure shows all events occurring with a rate of ≥2% overall.